Zhenzhen Liu

17PUBLICATIONS
26CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Models of care and place of birthEpidemiological modellingCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Sep 29, 2026
Neoadjuvant anti-HER2 antibody-drug conjugate SHR-A1811 in Hormone Receptor-positive, HER2-low Breast Cancer: A Phase 2 Clinical Trial (HELEN-015).

|Apr 29, 2026
C-type lectin domain family 5 member A-mediated activation of macrophages via a bispecific antibody enhances anti-HER2 therapy.

|Nov 13, 2025
Prognostic significance of HER2-low and HER2-zero status before and after neoadjuvant chemotherapy in patients with HER2-negative breast cancer.

Youzhao Ma, Jingyang Zhang, Lina Wang

|Aug 25, 2025
Impact of postoperative complications on patient-reported outcomes in deep inferior epigastric perforator flap breast reconstruction.

Xuhui Guo, Xilong Gong, Lina Wang

|Apr 22, 2025
Application of Neoadjuvant Docetaxel plus Cisplatin in Early-Stage Triple-Negative Breast Cancer (HELEN-001): Results from a Phase II Trial.

Dechuang Jiao, Jianghua Qiao, Xianfu Sun

|May 13, 2024
Assessment of the impact of residual tumors at different sites post-neoadjuvant chemotherapy on prognosis in breast cancer patients and development of a disease-free survival prediction model.

Hanzhao Yang, Yuxia Ruan, Yadong Sun

Pageof 3

Frequent Collaborators

4 joint publications

Min Yan

2 joint publications

Jiao Zhang

2 joint publications

Youzhao Ma

1 joint publications

Shuochuan Liu